Levofloxacin in treatment of 70 patients with bacterial infections
Abstract
AIM: To observe the efficacy and safety of levofloxacin (LVFX) in the treatment of bacterial infections. METHODS: Seventy patients (M 35, F 35; age 54±s 15 a) were treated with LVFX, including 40 patients with lower respiratory tract infections and 30 patients with urinary tract infections. The dosage was 0.2 g, po, bid for 7_14 d, except that in uncomplicated urinary tract infections the dosage was 0.2 g, po, qd for 5_7 d. RESULTS: The total effective rate and bacterial elimination rate were 93% and 88%, respectively. The adverse reactions of LVFX 6% were mild and transient. CONCLUSION: LVFX is effective and safe in the treatment of bacterial infections.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.